NASDAQ:TGTX • US88322Q1085
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for TG THERAPEUTICS INC (TGTX).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-02-02 | JP Morgan | Maintains | Overweight -> Overweight |
| 2026-01-15 | Goldman Sachs | Maintains | Neutral -> Neutral |
| 2025-11-03 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-09-17 | B. Riley Securities | Maintains | Buy -> Buy |
| 2025-03-04 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-01-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-11-25 | JP Morgan | Maintains | Overweight -> Overweight |
| 2024-11-05 | Goldman Sachs | Maintains | Neutral -> Neutral |
| 2024-11-05 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-10-29 | TD Cowen | Initiate | Buy |
| 2024-09-18 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-08-07 | B. Riley Securities | Maintains | Buy -> Buy |
| 2024-08-07 | Goldman Sachs | Maintains | Neutral -> Neutral |
| 2024-08-06 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-05-02 | Ladenburg Thalmann | Maintains | Buy -> Buy |
| 2024-05-02 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-04-18 | Ladenburg Thalmann | Reiterate | Buy -> Buy |
| 2024-04-18 | JP Morgan | Reiterate | Overweight -> Overweight |
| 2024-04-18 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-03-01 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-02-29 | Goldman Sachs | Maintains | Neutral -> Neutral |
| 2024-02-28 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-02-05 | B. Riley Securities | Maintains | Buy -> Buy |
| 2024-01-11 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-11-01 | JP Morgan | Maintains | Overweight -> Overweight |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 233.662M 8,290.02% | 329.004M 40.80% | 616.287M 87.32% | 916.72M 48.75% | 1.146B 25.01% | 1.508B 31.59% | 1.762B 16.84% | 1.978B 12.26% | 2.231B 12.79% | 2.444B 9.55% | 2.652B 8.51% | |
| EBITDA YoY % growth | 20.844M 109.56% | 41.997M 101.48% | 123.383M 193.79% | 255.39M 106.99% | 427.06M 67.22% | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | 20.633M 109.45% | 41.929M 103.21% | 123.324M 194.13% | 295.9M 139.94% | 472.04M 59.53% | 640.76M 35.74% | 768.95M 20.01% | 881.13M 14.59% | 1.068B 21.21% | 1.191B 11.52% | 1.313B 10.24% | |
| Operating Margin | 8.83% | 12.74% | 20.01% | 32.28% | 41.19% | 42.49% | 43.64% | 44.55% | 47.87% | 48.73% | 49.51% | |
| EPS YoY % growth | 0.01 100.68% | 0.14 1,300.00% | 0.50 257.14% | 1.61 221.55% | 2.33 45.07% | 3.11 33.27% | 3.76 20.92% | 4.19 11.40% | 5.76 37.64% | N/A | N/A |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|
| EPS Q2Q % growth | 0.33 998.68% | 0.39 128.98% | 0.46 187.79% | 0.52 272.79% |
| Revenue Q2Q % growth | 204.21M 68.97% | 220.37M 56.13% | 235.04M 45.35% | 254.59M 32.20% |
| EBITDA Q2Q % growth | 58.073M 572.92% | 68.279M 95.84% | 81.236M 176.28% | N/A |
| EBIT Q2Q % growth | 61.11M 608.77% | 69.629M 99.84% | 82.181M 179.86% | 92.922M 84.03% |
All data in USD
15 analysts have analysed TGTX and the average price target is 45.05 USD. This implies a price increase of 42.97% is expected in the next year compared to the current price of 31.51.
TG THERAPEUTICS INC (TGTX) will report earnings on 2026-05-04.
The consensus EPS estimate for the next earnings of TG THERAPEUTICS INC (TGTX) is 0.33 USD and the consensus revenue estimate is 204.21M USD.
The expected long term growth rate for TG THERAPEUTICS INC (TGTX) is 33.89%.